ERBB2 and neoplasm: Patient samples that had previously been stained with a commercial IHC kit and diagnosed with a HER2 status were tested with anti-ICD and anti-ECD HER2 antibodies, which identified a subset of HER2- patients whose tumours exhibited phosphorylated HER2 ICD’s and activated Akt/MAPK pathways [144].